Lazard Asset Management
LFCR icon

Lazard Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Lazard Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-277
Closed -$1K – 2420
2024
Q3 		$1K Buy
+277
New +$1.45K ﹤0.01% 2171
2022
Q1 		– Sell
-6,655
Closed -$73K – 2436
2021
Q4 		$73K Buy
+6,655
New +$64.6K ﹤0.01% 1567
2020
Q2 		– Sell
-879
Closed -$7K – 1708
2020
Q1 		$7K Buy
879
+281
+47% +$2.92K ﹤0.01% 1513
2019
Q4 		$6K Hold
598
– – ﹤0.01% 1421
2019
Q3 		$6K Buy
+598
New +$6.51K ﹤0.01% 1350

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management's LFCR Position: Q4 2024 in Review

Lazard Asset Management sold out of Lifecore Biomedical (LFCR) in Q4 2024, closing a stake of 277 shares — an estimated $1K sold.

Lazard Asset Management first reported a position in LFCR in Q3 2019 and held it in 5 quarters. The position peaked at $73K in Q4 2021. 77 funds tracked by Wall St. Rank hold LFCR as of Q4 2024.

  • Lazard Asset Management reported no remaining Lifecore Biomedical position as of Q4 2024 after selling out during the quarter.
  • Lazard Asset Management sold 277 Lifecore Biomedical shares in Q4 2024, an estimated $1K.
  • Lazard Asset Management first reported a position in Lifecore Biomedical in Q3 2019 and held it in 5 quarters.
  • Lazard Asset Management's Lifecore Biomedical position peaked at $73K in Q4 2021.
  • 77 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2024.

Based on Lazard Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.